Switching to guselkumab shows improved on-label persistence in psoriasis, indicating better disease control.
Patients experiencing suboptimal outcomes with other psoriasis-indicated advanced therapies achieved higher on-label persistence after switching to guselkumab, raising the potential for improved disease control relative to other treatment options.
No takes yet. Share an insight, caveat, or question.
Zhdanava et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: